Galecto Inc
GLTO
View Detailed Chart
2.870USD
0.000
Close 09/19, 16:00（ET）Quotes delayed by 15 min
3.80MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
0.00%
5 Days
0.00%
1 Month
-14.84%
6 Months
-32.15%
Year to Date
-38.28%
1 Year
-79.20%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated: 2025-09-19Key Insights
Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a . The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
0
analysts
--
Current Rating
6.000
Target Price
+99.34%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Galecto, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel treatments for cancer and liver diseases. The Company’s pipeline consists small molecule drug candidates that target cancer and fibrosis signaling pathways, including an orally active galectin-3 inhibitor (GB1211) for the treatment of liver cirrhosis; an orally active galectin-3 inhibitor (GB1211) in combination with a checkpoint inhibitor for various oncology indications; and a preclinical dual inhibitor of ENL-YEATS and FLT3 (BRM-1420) for multiple genetic subsets of acute myeloid leukemia (AML). The GB1211, is also being developed for the treatment of non-small cell lung cancer (NSCLC), melanoma, head and neck squamous cell carcinoma (HNSCC), and decompensated cirrhosis.
Fairly Valued
The company’s latest PE is -0.22, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 237.90K shares, decreasing 53.59% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 14.54K shares of this stock.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
Galecto, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel treatments for cancer and liver diseases. The Company’s pipeline consists small molecule drug candidates that target cancer and fibrosis signaling pathways, including an orally active galectin-3 inhibitor (GB1211) for the treatment of liver cirrhosis; an orally active galectin-3 inhibitor (GB1211) in combination with a checkpoint inhibitor for various oncology indications; and a preclinical dual inhibitor of ENL-YEATS and FLT3 (BRM-1420) for multiple genetic subsets of acute myeloid leukemia (AML). The GB1211, is also being developed for the treatment of non-small cell lung cancer (NSCLC), melanoma, head and neck squamous cell carcinoma (HNSCC), and decompensated cirrhosis.
Ticker SymbolGLTO
CompanyGalecto Inc
CEODr. Hans T. Schambye, M.D., Ph.D.
Websitehttps://galecto.com/
Related Instruments
+0.68%
+1.38%
-2.48%
-1.57%
-0.75%
-0.09%
+1.34%
-1.77%
-0.67%
-3.03%
-0.85%
-0.87%
-0.50%
+0.44%
-0.19%
-1.18%
-2.84%
0.00%
+0.30%
-3.72%
